NCT03038451

Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients

Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients: Open-label, Local, Phase IV Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Neutec Ar-Ge San ve Tic A.Ş · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

s-amlodipine besylate 2,5 mg tablet will be administered to patients have not received any hypertension treatment before or have received any of anti-hypertensive mono-therapy for the first four weeks of treatment. By increasing dose, s-amlodipine besylate 5 mg tablet will be administered for the last four weeks (4-8 weeks).

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet

Timeline

• Start date: 2013-03-20
• Primary completion: 2017-02-14
• Completion: 2017-02-14
• First posted: 2017-01-31
• Last updated: 2018-06-15

Locations

1 site across 1 country: Turkey (Türkiye)